[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100427929":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":48,"responsibleParty":64,"collaborators":43,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":43,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":43,"maxAge":43,"enrollmentInfo":75,"targetDuration":43,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":50,"whyStopped":43,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL","Participants in this group receive protocol-based management of perioperative antithrombotic therapy.",[13],"Drug: Protocol-based management of perioperative antithrombotic therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","SHAM_COMPARATOR","Participants in this group receive routine management of perioperative antithrombotic therapy.",[19],"Drug: Routine management of perioperative antithrombotic therapy",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Protocol-based management of perioperative antithrombotic therapy","Perioperative antithrombotic therapy is managed according to the latest expert consensus published in the Chinese Medical Journal, 2020.",[9],[27],"Protocol-based management",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Routine management of perioperative antithrombotic therapy","Perioperative antithrombotic therapy is managed according to current routine practice.",[15],[33],"Routine management",[35],{"name":36,"affiliation":5,"role":37},"Hong Zhang","PRINCIPAL_INVESTIGATOR",[39,45],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Hong Zhang, MD","CONTACT","86 10 83572784",null,"zhanghong40@hotmail.com",{"name":46,"role":41,"phone":43,"phoneExt":43,"email":47},"Huai-Jin Li, MD","crystal_35@163.com",[49],{"facility":5,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"RECRUITING","Beijing","Beijing Municipality","100034","China","CN",{"type":57,"coordinates":58},"Point",[59,60],116.39723,39.9075,{"lat":60,"lon":59},[63],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},{"type":37,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":43,"oldOrganization":43},"Dong-Xin Wang","Professor","100427929","protocol-based-management-and-perioperative-outcomes-in-patients-with-chronic-antithrombotic-therapy-100427929",false,"NCT04852406","Protocol-based Management and Perioperative Outcomes in Patients With Chronic Antithrombotic Therapy","Effect of Protocol-based Management on Perioperative Outcomes in Patients With Chronic Antithrombotic Therapy: a Pragmatic Interventional Study","Inclusion Criteria:\n\n* 1\\. Patients with continuing antithrombotic therapy (including antiplatelet and\u002For anticoagulant therapies) for cardiovascular and cerebrovascular diseases for more than 2 weeks.\n* 2\\. Patients who have one or more of the following situations: (1) non-valvular atrial fibrillation with a CHA2DS2-VASc score \\>4; (2) post-artificial valve replacement (including mitral valve, ball-cage valve or tilting disc aortic valve); (3) venous thromboembolism occurred within 1 year, or venous thromboembolism with other high-risk factors which require long-term anticoagulation treatment; (4) coronary heart disease with coronary stent implantation, thrombolytic therapy or other coronary procedures within 2 years, or who had undergone coronary artery bypass grafting within 1 year, or who experienced myocardial infarction or acute coronary syndrome within 1 year; (5) a history of stroke\u002Ftransient ischemic accident within 1 year, or a history of cervical or intracranial revascularization treatment within 1 year; (6) peripheral arterial disease.\n* 3\\. Patients who are scheduled to undergo intra-abdominal surgery (including general and urologic surgery).\n* 4\\. Patients who sign written informed consents.\n\nExclusion Criteria:\n\n* 1\\. Refuse to participate.\n* 2\\. Emergency surgery.\n* 3\\. Unable to complete the preoperative assessment and follow-up plan.\n* 4\\. Other reasons that are considered unsuitable for study participation by the investigators or the attending doctors.","ALL",{"count":76,"type":77},526,"ESTIMATED","INTERVENTIONAL",[80],"NA","The purpose of this pragmatic interventional study is to evaluate whether a protocol-based management of antithrombotic drugs can reduce a composite of perioperative outcomes in patients with chronic antithrombotic therapy before surgery.",[83,84,85],"Antithrombotic Therapy","Perioperative Care","Perioperative Outcomes",[87,88,89],"perioperative care","antithrombotic therapy","perioperative outcomes","2025-07-30",{"date":92,"type":93},"2025-07-31","ACTUAL",{"date":95,"type":93},"2021-04-21",{"date":97,"type":77},"2026-01",{"name":5,"class":6},1]